Mesoblast (MESO) Cash & Current Investments (2015 - 2025)
Mesoblast's (MESO) quarterly Cash & Current Investments came in at $130.0 million in Q4 2025, up 241.78% year-on-year from $38.0 million in Q4 2024, and down 19.55% quarter-over-quarter from $161.6 million in Q2 2025.
Mesoblast (MESO) Cash & Current Investments (2015 - 2025) Analysis & Trends
Mesoblast has disclosed Cash & Current Investments across 11 years of filings, most recently posting $130.0 million for Q4 2025.
- Cash & Current Investments for Q4 2025 came in at $130.0 million, up 241.78% year-over-year; the trailing twelve-month figure through Dec 2025 was $130.0 million (up 241.78% YoY), and the FY2025 annual result was $161.6 million, up 156.59% from the prior year.
- Cash & Current Investments came in at $130.0 million for Q4 2025 at Mesoblast, down from $161.6 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $161.6 million in Q2 2025 to a low of $38.0 million in Q4 2024.
- The 5-year median for Cash & Current Investments is $77.6 million (2023), against an average of $92.4 million.
- Across the five-year window, Cash & Current Investments sank 55.84% in 2022 and jumped 241.78% in 2025, its largest moves.
- Mesoblast's Cash & Current Investments stood at $94.8 million in 2021, then declined by 28.71% to $67.6 million in 2022, then gained by 14.69% to $77.6 million in 2023, then tumbled by 50.96% to $38.0 million in 2024, then surged by 241.78% to $130.0 million in 2025.
- The last three Cash & Current Investments figures came in at $130.0 million (Q4 2025), $161.6 million (Q2 2025), and $38.0 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Mesoblast | 21.68 Bn | 21.55 Bn | - | 129.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 129.98 Mn |
| Jun 30, 2025 | 161.55 Mn |
| Dec 31, 2024 | 38.03 Mn |
| Jun 30, 2024 | 62.96 Mn |
| Dec 31, 2023 | 77.55 Mn |
| Jun 30, 2023 | 71.32 Mn |
| Mar 31, 2023 | 48.80 Mn |
| Dec 31, 2022 | 67.62 Mn |
| Sep 30, 2022 | 85.50 Mn |
| Jun 30, 2022 | 60.45 Mn |
| Mar 31, 2022 | 76.76 Mn |
| Dec 31, 2021 | 94.85 Mn |
| Sep 30, 2021 | 115.96 Mn |
| Jun 30, 2021 | 136.88 Mn |
| Mar 31, 2021 | 158.26 Mn |
| Dec 31, 2020 | 129.33 Mn |
| Sep 30, 2020 | 108.12 Mn |
| Jun 30, 2020 | 129.33 Mn |
| Mar 31, 2020 | 60.08 Mn |
| Dec 31, 2019 | 81.35 Mn |